3 completed, 1 recruiting, 1 withdrawn. 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 5 | Completed 3, Recruiting 1, Withdrawn 1 |
Follow QVM149: new trials by email Literature Review of QVM149 trials Research Report on QVM149
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma. QVM149, Salmeterol Xinafoate / Fluticasone Propionate, Placebo to QVM149 - Asthma | Phase 3 | Recruiting | Novartis Pharmaceuticals | 188 | 2026-08-04 | 2026-11-10 |
| Investigating the Effects of QVM149 on MRI Ventilation Defects QVM149, High Dose Dual Therapy (ICS/LABA) - Asthma | Phase 3 | Withdrawn | Dr. Grace Parraga | 2021-12-01 | 2021-12-14 | |
| Anti-inflammatory Effects Glycopyrronium QVM149, QMF149 - Asthma, Allergic Asthma | Phase 3 | Completed | University Medical Center Groningen | 28 | 2020-09-10 | 2023-01-12 |
| Study to Compare QVM149 and Free Triple Combination of Salmeterol/Fluticasone + Tiotropium QVM149, Salmeterol/fluticasone plus tiotropium - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 1426 | 2018-02-05 | 2021-10-08 |
| A Long-term Safety Study of QVM149 in Japanese Patients With Asthma QVM149 - Asthma | Phase 3 | Completed | Novartis Pharmaceuticals | 96 | 2017-04-28 | 2020-04-07 |
Novartis Pharmaceuticals (3) · Dr. Grace Parraga (1) · University Medical Center Groningen (1)
Argentina (2) · Germany (2) · Hungary (2) · Poland (2) · Slovakia (2) · South Africa (2) · Spain (2) · Taiwan (2) · Canada (1) · Chile (1) · Colombia (1) · Czechia (1) · France (1) · Greece (1) · India (1)
Grace E Parraga, PhD (1) · Maarten Van den Berge, Dr. (1)
2017 (1)